EBR Systems (ASX:EBR) said the US Food and Drug Administration completed the manufacturing pre-approval inspection of its facilities with no material observations made, according to a Monday filing with the Australian bourse.
The company expects regulatory approval by Apr. 13, with commercial launch expected in the second half of the year, the filing said.
Shares fell 1% in morning trade Monday but earlier reached an all-time high.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.